IL1B and irritable bowel syndrome: This could be attributed to a number of factors relating to the use of IBS-20 in vivo including the inability to inhibit the TNBS-induced epithelial barrier breakdown or to block production of IL-1β, a major pro-inflammatory cytokine implicated in TNBS-induced colonic inflammation.